{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:46Z","timestamp":1740144106315,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40268-023-00440-8","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:02:45Z","timestamp":1695729765000},"page":"411-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Tucatinib on Cardiac Repolarization in Healthy Volunteers"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct03777761","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ariel R.","family":"Topletz-Erickson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAl G.","family":"Mayor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsu-Tai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layth I.","family":"Abdulrasool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Endres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"440_CR1","unstructured":"E14 Implementation Working Group. ICH E14 guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions & answers (R3). Available at: https:\/\/database.ich.org\/sites\/default\/files\/E14_Q%26As_R3_Q%26As.pdf. Accessed 23 Mar 2023."},{"issue":"5","key":"440_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/annonc\/mdy100","volume":"29","author":"S Siena","year":"2018","unstructured":"Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz H, McCall S, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108\u201319. https:\/\/doi.org\/10.1093\/annonc\/mdy100.","journal-title":"Ann Oncol"},{"issue":"4","key":"440_CR3","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.Mct-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19(4):976\u201387. https:\/\/doi.org\/10.1158\/1535-7163.Mct-19-0873.","journal-title":"Mol Cancer Ther"},{"key":"440_CR4","unstructured":"Seagen Inc. Tukysa (tucatinib): European summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tukysa-epar-product-information_en.pdf. Accessed 12 Jan 2023."},{"key":"440_CR5","unstructured":"US FDA. TUKYSA US Prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213411s004lbl.pdf. Accessed 6 Mar 2023."},{"issue":"7","key":"440_CR6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1914609.","journal-title":"N Engl J Med"},{"issue":"3","key":"440_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"G Curigliano","year":"2022","unstructured":"Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.005.","journal-title":"Ann Oncol"},{"key":"440_CR8","unstructured":"US FDA. Multi-disciplinary review and evaluation-NDA 213411 (tucatinib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213411Orig1s000MultidisciplineR.pdf. Accessed 4 Mar 2023."},{"issue":"12","key":"440_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s40262-022-01183-6","volume":"61","author":"AR Topletz-Erickson","year":"2022","unstructured":"Topletz-Erickson AR, Lee AJ, Mayor JG, Sun H, Abdulrasool LI, Rustia EL, et al. The pharmacokinetics and safety of tucatinib in volunteers with hepatic impairment. Clin Pharmacokinet. 2022;61(12):1761\u201370. https:\/\/doi.org\/10.1007\/s40262-022-01183-6.","journal-title":"Clin Pharmacokinet"},{"key":"440_CR10","doi-asserted-by":"crossref","unstructured":"Strickler JH, Cercek A, Siena S, Andre T, Ng K, Van Cutsem E, et al. Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2 positive mCRC [abstract LBA-2]. European Society of Medical Oncology World Congress on Gastrointestinal Cancer; 2022.","DOI":"10.1016\/j.annonc.2022.04.440"},{"issue":"6","key":"440_CR11","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/ijms20061324","volume":"20","author":"RM Lester","year":"2019","unstructured":"Lester RM, Paglialunga S, Johnson IA. QT assessment in early drug development: the long and the short of it. Int J Mol Sci. 2019;20(6):1324. https:\/\/doi.org\/10.3390\/ijms20061324.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"440_CR12","first-page":"473","volume":"42","author":"M Li","year":"2017","unstructured":"Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. P T. 2017;42(7):473\u20137.","journal-title":"P T"},{"issue":"2","key":"440_CR13","doi-asserted-by":"publisher","first-page":"188355","DOI":"10.1016\/j.bbcan.2020.188355","volume":"1873","author":"S He","year":"2020","unstructured":"He S, Moutaoufik MT, Islam S, Persad A, Wu A, Aly KA, et al. HERG channel and cancer: a mechanistic review of carcinogenic processes and therapeutic potential. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188355. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188355.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"22","key":"440_CR14","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.4155\/bio-2022-0199","volume":"14","author":"JA Meyer","year":"2023","unstructured":"Meyer JA, DeChenne S, Foerder CA, Hengel SM. Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis. Bioanalysis. 2023;14(22):1443\u201352. https:\/\/doi.org\/10.4155\/bio-2022-0199.","journal-title":"Bioanalysis"},{"issue":"4","key":"440_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1542-474x.2003.08413.x","volume":"8","author":"LS Fridericia","year":"2003","unstructured":"Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol. 2003;8(4):343\u201351. https:\/\/doi.org\/10.1046\/j.1542-474x.2003.08413.x.","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"3","key":"440_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/10543400903581945","volume":"20","author":"LK Yan","year":"2010","unstructured":"Yan LK, Zhang J, Ng MJ, Dang Q. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat. 2010;20(3):497\u2013507. https:\/\/doi.org\/10.1080\/10543400903581945.","journal-title":"J Biopharm Stat"},{"issue":"10","key":"440_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s40262-022-01144-z","volume":"61","author":"A Topletz-Erickson","year":"2022","unstructured":"Topletz-Erickson A, Lee A, Rustia EL, Sun H, Mayor JG, Abdulrasool LI, et al. Evaluation of safety and clinically relevant drug-drug interactions with tucatinib in healthy volunteer\ufeffs. Clin Pharmacokinet. 2022;61(10):1417\u201326. https:\/\/doi.org\/10.1007\/s40262-022-01144-z.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"440_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/toxsci\/kfy239","volume":"167","author":"J Huo","year":"2019","unstructured":"Huo J, Wei F, Cai C, Lyn-Cook B, Pang L. Sex-related differences in drug-induced QT prolongation and Torsades de Pointes: a new model system with human iPSC-CMs. Toxicol Sci. 2019;167(2):360\u201374. https:\/\/doi.org\/10.1093\/toxsci\/kfy239.","journal-title":"Toxicol Sci"},{"issue":"11","key":"440_CR19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","volume":"89","author":"YG Yap","year":"2003","unstructured":"Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363\u201372. https:\/\/doi.org\/10.1136\/heart.89.11.1363.","journal-title":"Heart"},{"key":"440_CR20","doi-asserted-by":"publisher","first-page":"613625","DOI":"10.3389\/fcvm.2021.613625","volume":"8","author":"P Kim","year":"2021","unstructured":"Kim P, Masha L, Olson A, Iliescu C, Karimzad K, Hassan S, et al. QT prolongation in cancer patients. Front Cardiovasc Med. 2021;8:613625. https:\/\/doi.org\/10.3389\/fcvm.2021.613625.","journal-title":"Front Cardiovasc Med."},{"key":"440_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40959-020-0057-2","volume":"6","author":"Y Lin","year":"2020","unstructured":"Lin Y, Yu H, Liu F, Chen C, Zhang Y, Wang B, et al. Hospitalized cancer patients with acquired long QT syndrome-a matched case-control study. Cardiooncology. 2020;6:3. https:\/\/doi.org\/10.1186\/s40959-020-0057-2.","journal-title":"Cardiooncology."},{"issue":"4","key":"440_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jpainsymman.2019.12.356","volume":"59","author":"JR Hardy","year":"2020","unstructured":"Hardy JR, Bundock D, Cross J, Gibbons K, Pinkerton R, Kindl K, et al. Prevalence of QTc prolongation in patients with advanced cancer receiving palliative care-a cause for concern? J Pain Symptom Manag. 2020;59(4):856\u201363. https:\/\/doi.org\/10.1016\/j.jpainsymman.2019.12.356.","journal-title":"J Pain Symptom Manag"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00440-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00440-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00440-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:15:11Z","timestamp":1700903711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00440-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00440-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"24 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this publication was provided by Seagen Inc., Bothell, WA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors wrote this article with the assistance of a medical writer funded by the sponsor. All authors had full access to the relevant data, vouch for the completeness and accuracy of the data and for adherence of the trial to the protocol, and assume final responsibility for the content of the article and the decision to submit the article for publication. Ariel R. Topletz-Erickson, JoAl G. Mayor, Hsu-Tai Liu, Layth I. Abdulrasool, and Christopher J. Endres are employees of Seagen and hold stocks and shares in Seagen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Qualified researchers may request access to certain data and related study documents consistent with the Principles for Responsible Clinical Trial Data Sharing. Interested researchers can use  to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Before the start of this study, the study protocol and informed consent form were approved by a central Institutional Review Board (Midlands Independent Review Board, Overland Park, KS, USA). All amendments to the protocol were also approved by the Institutional Review Board. The study was designed and implemented in accordance with the International Council for Harmonisation of Technical Requirements for Human Use (ICH) E14 guidance on The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs []. The study was also conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regional and local legislation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written consent prior to study enrolment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors contributed to the study design; analysis and interpretation of the data; and critical revisions of the article. All authors provided final approval for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All participants provided written consent prior to study enrolment.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}